U.S. FDA Approves Orexo's Low Dose ZUBSOLV(R) Buprenorphine and Naloxone Sublingual Tablets (CIII)

MORRISTOWN, N.J., Oct. 6, 2016 — (Healthcare Sales & Marketing Network) — Orexo US announced today that the U.S. Food and Drug Administration (FDA) has approved ZUBSOLV® (buprenorphine/naloxone CIII sublingual tablet) 0.7mg/0.18mg for the treatment … Biopharmaceuticals, FDA Orexo, ZUBSOLV, buprenorphine, naloxone (Source: HSMN NewsFeed)